S235: A TWO-PART, SINGLE- AND TWO-ARM RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE S1P RECEPTOR MODULATOR KRP203 IN SUBJECTS WITH HEMATOLOGICAL MALIGNANCIES

• S. dertschnig,
• J. finke,
• D. heim,
• U. schanz,
• E. holler,
• U. holtick,
• G. socié,
• T. teshima,
• C. bucher,
• J. passweg

Affiliations

S. dertschnig

1 Priothera SAS, Saint Louis, France

J. finke

2 Heamtology, Oncology and SCT, University Freiburg, Freiburg, Germany

D. heim

3 Hematology, University Hosptial Basel, Basel

U. schanz

4 University Hospital Zürich, Zürich, Switzerland

E. holler

5 Klinik und Poliklinik Innere Medizin III, Unuversitätsklinikum Regensburg, Regensburg

U. holtick

6 Klinik I für Innere Medizin, Köln, Germany

G. socié

7 Saint Louis Hospital, Paris, France

T. teshima

8 Hokkaido University, Faculty of Medicine, Sapporo, Japan

C. bucher

9 Universtity Hospital Basel

J. passweg

10 University Hosptial Basel, Basel, Switzerland